Truvada (emtricitabine / tenofovir disoproxil) vs Vocabria (cabotegravir)
Truvada (emtricitabine / tenofovir disoproxil) vs Vocabria (cabotegravir)
Truvada (emtricitabine/tenofovir disoproxil) is an oral medication taken daily for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection, and it's also used in combination with other medications to treat HIV. Vocabria (cabotegravir), on the other hand, is an injectable medication administered initially as an oral lead-in to assess tolerability, followed by intramuscular injections every two months for PrEP, offering an alternative to daily pill-taking. When deciding between the two, patients should consider factors such as their preference for daily versus less frequent dosing, potential side effects, kidney function, and their overall adherence to treatment regimens, in consultation with their healthcare provider.
Difference between Truvada and Vocabria
Metric | Truvada (emtricitabine / tenofovir disoproxil) | Vocabria (cabotegravir) |
---|---|---|
Generic name | Emtricitabine / Tenofovir disoproxil | Cabotegravir |
Indications | HIV-1 infection prevention and treatment | HIV-1 infection treatment (as part of a combination therapy) |
Mechanism of action | Reverse transcriptase inhibitors | Integrase strand transfer inhibitor (INSTI) |
Brand names | Truvada | Vocabria |
Administrative route | Oral | Oral, Injectable (long-acting formulation) |
Side effects | Nausea, diarrhea, headache, fatigue, dizziness | Fever, fatigue, headache, muscle pains, injection site reactions |
Contraindications | Patients with hypersensitivity to the active substances or any of the excipients | Patients with hypersensitivity to the active substance or any of the excipients |
Drug class | Nucleoside reverse transcriptase inhibitors (NRTIs) | Integrase strand transfer inhibitor (INSTI) |
Manufacturer | Gilead Sciences | ViiV Healthcare |
Efficacy
Efficacy of Truvada in HIV/AIDS Prevention and Treatment
Truvada, a combination of emtricitabine and tenofovir disoproxil, is a medication that has been widely used in the treatment and prevention of HIV/AIDS. In the context of treatment, Truvada is part of antiretroviral therapy (ART) regimens for individuals who are living with HIV. It works by inhibiting the action of reverse transcriptase, an enzyme crucial for the replication of HIV. Clinical trials and studies have consistently shown that Truvada, when used in combination with other antiretroviral agents, is highly effective in reducing viral load to undetectable levels and in improving CD4 cell counts, which are key indicators of immune system health.
For HIV prevention, Truvada is used as pre-exposure prophylaxis (PrEP). It is intended for individuals who are at high risk of acquiring HIV, such as those with an HIV-positive sexual partner. Studies have demonstrated that when taken consistently, Truvada can reduce the risk of sexually acquired HIV infection by a significant margin. The US Centers for Disease Control and Prevention (CDC) supports its use as an effective preventive measure, alongside other risk-reduction strategies.
Efficacy of Vocabria (Cabotegravir) in HIV/AIDS Prevention
Vocabria, which contains the active ingredient cabotegravir, is a newer medication that has been evaluated for its efficacy in HIV prevention. Unlike Truvada, which is taken orally, Vocabria is administered as an intramuscular injection. It is used as part of a regimen for pre-exposure prophylaxis (PrEP) and is designed for individuals who are at risk of HIV but have difficulty adhering to a daily oral medication regimen. Clinical trials have shown that cabotegravir injections, given every two months, are highly effective in reducing the risk of HIV acquisition in men who have sex with men (MSM) and transgender women who have sex with men, populations that are at high risk for HIV.
One of the pivotal trials for Vocabria, the HPTN 083 study, compared the efficacy of long-acting injectable cabotegravir to daily oral Truvada for PrEP. The results indicated that cabotegravir was superior to Truvada in preventing HIV acquisition in the study population. The trial demonstrated a 66% reduction in HIV incidence among participants receiving cabotegravir compared to those receiving Truvada. This finding has positioned Vocabria as a promising alternative for PrEP, offering a less frequent dosing schedule that may improve adherence and overall prevention outcomes.
Regulatory Agency Approvals
Truvada
Vocabria
Access Truvada or Vocabria today
If Truvada or Vocabria are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us